Patent focus on cancer chemotherapeutics. III Angiogenesis agents: October 2000 - March 2001

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 7, 2001, Pages 1171-1203

  Connell, R D ^a   Beebe, J S ^a  

^a PFIZER INC   (United States)

Author keywords

v 3; v 5; Angiogenesis; Angiopoietin; Angiostatin; Cancer; Endostatin; Fibroblast growth factor (FGF); Flavinoids; Flt; Gelatinase; Growth factor inhibitors; HGF; Integrin antagonists; KDR; Kringle Matrix metalloprotease (MMP); Metastasis; MMPI; Neovascularization; PDGF; Platelet factor 4; Receptor tyrosine kinases; RGD; Stromelysin; SU 5416; Tek; Thrombospondin; Tie 2; Tie2; TIMP; TKI; TMP 470; Tumour; uPAR; Urokinase; Vascular targeting; VEGF; Vitronectin

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; AMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA AMINO ACID; BISPHOSPHONIC ACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CGS 27023A; CIPEMASTAT; COLLAGENASE 3; GELATINASE; GELATINASE A; GROWTH FACTOR; HYDROXAMIC ACID DERIVATIVE; INTEGRIN; INTEGRIN INHIBITOR; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PROPIONIC ACID DERIVATIVE; PROTEIN INHIBITOR; PYRIMIDINE DERIVATIVE; REBIMASTAT; STROMELYSIN; STROMELYSIN 2; SULFONAMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; BONE MARROW CELL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; INHIBITION KINETICS; LUNG SMALL CELL CANCER; METASTASIS; MULTIPLE MYELOMA; PATENT; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STROMA CELL; TREATMENT FAILURE; TUMOR GROWTH;

EID: 0034945439     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.7.1171     Document Type: Review

References (67)

1. New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
2. 'Accidental' anti-angiogenic drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
3. Angiogenesis research. Cancer drugs found to work in new way
4. Cancer chemotherapeutics-angiogenesis agents: October 1999 - March 2000
5. Patent focus on cancer chemotherapeutics. II angiogenesis agents: April 2000 - September 2000
6. Current status of anti-angiogenic factors
7. Angiogenesis inhibitors - New agents in cancer therapy
8. Anti-angiogenic treatment of human cancer: Pitfalls and promises
9. Angiogenesis: New targets for the development of anticancer chemotherapies
10. Tumour vasculature as a target for anticancer therapy
11. Tumor angiogenesis: A novel therapeutic target in patients with malignant disease
12. MMPI demise spotlights target choice
13. British Biotech abandons marimastat
14. Marimastat shows signs of life
15. Development of matrix metalloproteinase inhibitors in cancer therapy
16. The design of selective non-substrate-based matrix metalloproteinase inhibitors
17. Ongoing trials with matrix metalloproteinase inhibitors
18. Preclinical development of metalloprotease inhibitors in cancer therapy
19. Synthesis and activity of selective MMP inhibitors with an aryl backbone
20. Clinical potential of matrix metalloprotease inhibitors in cancer therapy
21. Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor
22. Highly selective and orally active inhibitors of TYPE IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives
23. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors
24. Pharmacia's semaxanib embarks on global Phase III trial
25. Development of inhibitors for protein tyrosine kinases
26. Protein kinase inhibitors: Emerging pharmacophores 1997 - 2000
27. Selective tyrosine kinase inhibitors
28. VEGF: An update on biological and therapeutic aspects
29. FDA clears Novel Novartis Cancer Drug - Gleevec, to fight Leukemia
30. Novartis submits US & EU filing for Glivec
31. Involvement of platelet-derived growth factor in disease: Development of specific antagonists
32. SU6668 in neuroblastoma
33. MedImmune begins Phase 1 for Vitaxin second generation - MedImmune begins Phase II urinary tract infection vaccine trial
34. MedImmune and Targesome pursue vitaxin nanoparticle technology
35. Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides
36. New functions for non-collagenous domains of human collagen Type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo
37. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis
38. Wilex Presents Preclinical Data on WX UK1
39. (4-aminomethyl)-phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase
40. Crystals of the urokinase type plasminogen activator variant beta(c)-uPA in complex with small molecule inhibitors open the way towards structure-based drug design
41. New clinical data confirm endostatin's pharmacological profile in cancer patients and extend preclinical results
42. Entremed, Inc. signs agreement with Chiron Corporation to expand production of endostatin protein for Phase II clinical trials GMP manufacturing continues at Chiron Corporation
43. Interaction of endostatin with integrins implicated in angiogenesis
44. Endogenous regulators of angiogenesis - Emphasis on proteins with thrombospondin - Type I motifs
45. Thrombospondins as matricellular modulators of cell function
46. InKine Scientist Awarded NIH Grant to Study Angiocidin as an Inhibitor of Angiogenesis
47. New data on panzem demonstrates activity against a wide variety of cancers
48. EntreMed Phase II clinical trial program expands to include prostate cancer orally-active angiogenesis inhibitor 2ME2 now called panzem
49. Antiinflammatory and antitumor effects of flavonoids and flavanoids
50. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate
51. TNP-470: An angiogenesis inhibitor in clinical development for cancer
52. CA4P (combretastatin A4 prodrug) oxigene reports progress on CA4P
53. Matrix metalloproteinases as emerging targets in anticancer therapy: Status and prospects
54. Comparative specificity of platelet alpha(IIb)beta(3) integrin antagonists
55. Ligand binding to integrin alpha(v)beta(3) requires tyrosine 178 in the alpha(v) subunit
56. RGD mimetics containing a central hydantoin scaffold: Alpha(v)beta(3) vs. alpha(IIb)beta(3) selectivity requirements
57. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator
58. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite
59. Vertex receives patent for drug discovery targeting kinase gene family
60. The sequence of the human genome
61. International Human Genome Sequencing Consortium, Initial sequencing and analysis of the human genome
62. PTO publishes guidelines relating to gene patenting